Sirolimus Update and New Agents on the Horizon
Cincinnati's Children's Hospital Medical Center's Adrienne Hammill, M.D., Ph.D., provides updates on the Sirolimus medication as well as new agents on the horizon.
Dr. Hammill's goal is to advance the treatment of vascular anomalies, translating discoveries of the genetic and molecular etiologies of vascular anomalies into clinical practice. As a member of the multidisciplinary Hemangioma & Vascular Malformations Center (HVMC) at Cincinnati Children’s Hospital, Dr. Hammill provides care for patients with vascular anomalies. Genetic changes are rapidly being identified as causes of vascular anomalies, illuminating multiple genes and signaling pathways that are critical for normal vascular development. The PI3K/Akt/mTOR and MAPK pathways in particular are potential candidates for targeted treatments for vascular anomalies. As Research Director of HVMC, Dr. Hammill works with pharmaceutical companies to bring clinical drug trials to patients to improve their function and quality of life, while collaborating with basic scientists working to understand the biology underlying vascular anomalies and identify new potential therapies.
